SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
develop potential antibody treatments for Alzheimer's disease, ?the biotech firm said on Monday. Under the agreement, SciNeuro will receive $165 million upfront ?and could earn up to $1.5 billion tied to development, regulatory and sales milestones along with royalties on future sales. The deal would give Novartis access to SciNeuro's proprietary technology designed to improve ?the delivery of the ?drug to the brain. SciNeuro said the approach could differentiate its antibodies from approved treatments that are ?also designed to clear sticky deposits of a protein called amyloid beta, a hallmark of Alzheimer's. The search for new treatments for Alzheimer's is ?increasingly shifting to novel approaches that treat the memory-robbing ?disease as the product of multiple, complex biological pathways and researchers and drugmakers are pursuing new targets that could slow or halt its progression. Roche recently launched late-stage trials of its drug trontinemab, which links an amyloid
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- SciNeuro and Novartis Enter into a Licensing and Collaboration Agreement for Next Generation Therapeutics to Treat Alzheimer's Disease [Yahoo! Finance]Yahoo! Finance
- Gradalis Appoints Steven D. Weinstein as Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment [Yahoo! Finance]Yahoo! Finance
- Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investmentGlobeNewswire
- New Investors: 3 Stocks to Build Your Portfolio Around in 2026 [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 10/28/25 - Miss
NVS
Sec Filings
- 11/25/25 - Form 6-K
- 11/20/25 - Form 6-K
- 11/5/25 - Form 6-K
- NVS's page on the SEC website